Recently, with Trump elected as the new U.S. president, the entire healthcare industry has begun to worry about the potential impact on public health policy and the pharmaceuticals sector during his term.Although the election of a Republican president has traditionally been beneficial to the pharmaceutical industry, former President Trump hinted that he might allow Robert F. Kennedy Jr., an anti-vaccine conspiracy theorist, to play a significant role in the U.S. government’s food and health-related functions. Trump's running mate also suggested that Kennedy might serve as the Secretary of Health and Human Services (HHS). If that happens, vaccine manufacturers will surely be concerned about their orders with the government being affected.
Previously, we introduced Robert F. Kennedy Jr.'s background and related statements, as well as his campaign slogans. Clearly, he does not have a friendly attitude towards the infectious disease vaccine industry.But there may be a relatively friendly attitude towards industries related to hypoglycemic drugs, weight-loss drugs, and autoimmune diseases.Although it is hard to say whether this is beneficial to the entire pharmaceuticals industry, GSK, which has a significant stake in the vaccine sector, clearly has something to say. After all, GSK's recent growth driver has been its respiratory syncytial virus vaccine Arexvy, a major cash cow for the company. If government orders are impacted, the blow to GSK could be quite substantial.After Trump's victory, GSK CEO Emma Walmsley said at the Financial Times Global Pharmaceutical and Biotechnology Summit that Robert F. Kennedy Jr.'s slogan actually is "Make America Healthy Again"The idea is very good, but it requires constructive dialogue and transparent exchanges based on facts.After all, the average life expectancy in the United States is four years lower than the average of the Organization for Economic Cooperation and Development (OECD), and vaccination rates are even regressing, with 38 states having lower vaccination rates than the same period in 2019.Give the green light to mergers and acquisitionsSome analysts also believe that Trump's election this time could give the green light to mergers and acquisitions in the pharmaceuticals industry. Previously, when Amgen attempted to acquire Horizon Therapeutics, it was thwarted by the Federal Trade Commission (FTC). Particularly, Lina Khan, the head of the FTC, was a major obstacle. She was nominated by the Biden administration and holds a firm stance against monopolies.Some of her opponents said,Even among the Wall Street billionaires supporting Harris's campaign (such as media mogul Barry Diller and LinkedIn founder Reid Hoffman), some have set the condition of Lina Khan's resignation, calling her "a fool."Clearly, it has failed to satisfy either side.Analysts said that the Trump administration is unlikely to keep Lina Khan in her position. Jared Holz, a healthcare strategist at Mizuho, sharply pointed out in an investor report,Whether Lina Kha will be dismissed on Trump's first day in office is a key factor., even if the FTC changes little, this Trump administration may be more favorable to corporate mergers.How to Influence the IRA BillAll along, the Republican Party has been completely opposed to the Inflation Reduction Act (IRA) implemented during Biden's administration, with not a single Republican supporting the IRA.Similarly, Trump's team has consistently opposed reducing the clean energy sector within the IRA bill. His election could significantly impact the solar and wind power generation industries. However, regarding the pharmaceutical industry portion of the bill, Trump did not highlight it as a major agenda item during his campaign, suggesting that attention to this aspect may take a backseat.Analysts at BMO Capital Markets said that Trump's victory would signal to the market that "the IRA may not be expanded and could lose priority status due to financing considerations."In this regard, the main "victim" of the IRA, the Pharmaceutical Research and Manufacturers of America (PhRMA), may have more to say. After the election, PhRMA CEO Stephen J. Ubl celebrated Trump's victory and stated: "Look forward to working with him to build on the success of his first administration。”Such a statement is somewhat ironic, especially since Trump wasn't saying that in 2020 when he wanted to cut drug prices:The U.S. government "recklessly attacked the companies that have been working day and night to defeat COVID-19," and the order is "an irresponsible and unworkable policy."https://www.pharmaceutical-technology.com/news/gsk-ceo-addresses-declining-trust-in-vaccines-following-trump-re-election/?cf-viewhttps://phrma.org/Newsroom/PhRMA-Statement-on-the-2024-US-Electionhttps://www.fiercepharma.com/pharma/fiercepharmapolitics-trump-unveils-favored-nation-drug-pricing-executive-order-and-pharmaSource of Content:BioValley
Pharmacodia Media Business CooperationMedia PR | News &Press ReleaseManager Zhang: 18600036371 (Same for WeChat)Click "PharmSnap" below to follow more exciting content.
The article reproduced by the "PharmSnap" WeChat Official Account is sourced from another WeChat Official Account platform. The main purpose is to share relevant industry knowledge and convey the latest information. The copyrights of the images and articles belong to the original authors. If there is any infringement, please inform us in time, and we will delete the relevant information within 24 hours.The push rules of WeChat Official Accounts have changed again. If you don't tap"Under Observation"Or not set to"Star Mark", we might just dissipate in the vast sea of literature~ Click here, don't miss out on the latest news from PharmaDJ!??
